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Abstract
Metabolomics is the systemic study of all small molecules (metabolites) and their concentration as 
affected by pathological and physiological alterations or environmental or other factors. Metabolic 
alterations represent a “window” on the complex interactions between genetic expression, enzyme 
activity, and metabolic reactions. Techniques, including nuclear magnetic resonance spectroscopy, 
mass spectrometry, Fourier-transform infrared, and Raman spectroscopy, have led to significant 
advances in metabolomics. The field is shifting from feasibility studies to biological and clinical 
applications. Fields of application range from cancer biology to stem cell research and assessment 
of xenobiotics and drugs in tissues and single cells. Cross-validation across high-throughput 
platforms has allowed findings from expression profiling to be confirmed with metabolomics. 
Specific genetic alterations appear to drive unique metabolic programs. These, in turn, can be used 
as biomarkers of genetic subtypes of prostate cancer or as discovery tools for therapeutic targeting 
of metabolic enzymes. Thus, metabolites in blood may serve as biomarkers of tumor state, 
including inferring driving oncogenes. Novel applications such as these suggest that metabolic 
profiling may be utilized in refining personalized medicine.
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Introduction
The Human Genome Project and the subsequent publication of a reference human genome 
sequence[1] represent milestones in biology research in general and in cancer in particular. 
In the last decade, metabolomics has contributed greatly to the understanding of cancer 
biology. In analogy to genomics and proteomics, the term metabolomics can be defined as 
the study of the complete ensemble of all small molecules (molecular weight (MW) < 1500 
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Da) formed by numerous biosynthetic and catabolic pathways within a biological system or 
originating from host-specific microbes and the intake of food nutrients and 
pharmaceuticals, which are present in a cell, tissue, or biofluids such as urine,[2] blood,[3] 
or saliva,[4] in the context of a physiological or pathological condition.[5
In 2004, the Human Metabolome Project (HMP), the equivalent of the Human Genome 
Project for metabolomics, was created as an inventory of 2500 small molecules produced by 
metabolic reactions in the body's tissues and biofluids.[6] The publication of the third 
version of the Human Metabolome Database (HMDB)[7] presented a comprehensive, web-
accessible metabolomics database that brings together quantitative chemical, physical, 
clinical, and biological data on about 40,000 experimentally detected and biologically 
expected human metabolites.[7]
The major challenges of metabolomics stem from its advantages. While genomics and 
proteomics involve the study of molecules that are chemically similar or at least comparable, 
metabolomics deals with structurally heterogeneous and physico-chemically diverse small 
molecules. The range of their concentration spans up to nine orders of magnitude,[8] posing 
additional technical obstacles in terms of dynamic range and comparability. These small 
molecules or metabolites include compounds differing in chemical properties and function. 
These include, but are not limited to, lipids, sugars, ions, metabolic intermediates, and 
products of biochemical reactions, as well as building blocks for all other biochemical 
species including proteins, nucleic acids, and cell membranes.
Technology development, as well as new methods of data analysis,[10] has played a key role 
in driving the field of metabolomics. New methods and instrumentations, as well as 
incremental improvements in efficiency and sensitivity, have been fundamental for achieving 
the remarkable throughput and performance of this technology. Different techniques have 
been available to investigate the metabolome, distinguishing the different metabolites on the 
basis of their chemical and physical properties.
This review focuses on the rapidly developing analytical technologies, such as nuclear 
magnetic resonance (NMR), mass spectrometry (MS), Fourier-transform infrared (FT-IR), 
and Raman spectroscopy, but also discusses the most important steps in the workflow of 
metabolomic research.
Metabolic profiling in cancer is discussed using prostate cancer (PCa) as a paradigm. 
Specifically, cross-validation across high-throughput platforms has allowed findings from 
one type of biological data, expression profiling, to be confirmed with metabolomics, 
whereby specific genetic alterations are shown to drive unique metabolic programs. Thus, 
metabolites can be used as discovery tools for the identification of targetable metabolic 
enzymes or as biomarkers of genetic subtypes of PCa.
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Techniques utilized in the assessment of metabolites
Mass spectrometry
MS-based approaches are the most sensitive of all techniques. There are many types of mass 
analyzers, and each analyzer type has its strengths and weakness. With the recent advent of 
ultrahigh-accuracy mass spectrometers (i.e., the quadrupole time-of-flight geometry MS and 
FT-MS), there are interesting new prospects for quantitative analysis of ion species not 
possible with currently available MS analyzers.
MS is usually coupled with gas chromatography (GC) or liquid chromatography (LC) to 
separate different classes of metabolites. GC-MS is the most robust technique in MS-based 
metabolomics, widely used to identify and quantify volatile, thermally stable, low-
molecular-weight metabolites (<500 Da), such as organic acids, amino acids, nucleic acids, 
sugars, amines, and alcohols.[8] Polar and nonvolatile metabolites instead require chemical 
derivatization. On the other hand, LC offers several advantages over GC, including the 
possibility to separate compounds without chemical derivatization and at room temperature. 
LC-MS techniques are typically more sensitive and show a higher accuracy over a larger size 
range (from 800 to 2000 Da) than GC-MS techniques. GC-MS and LC-MS techniques can 
thus be considered complementary.
Nuclear magnetic resonance
NMR spectroscopy is particularly useful in the detection of compounds that are less 
tractable by GC-MS and LC-MS, such as amines, sugars, and volatile and nonreactive 
compounds. It is based on the detection of electromagnetic radiation emitted by nuclei of 
some isotopes (e.g., 1H, 13C, and 31P) when placed in a high magnetic field.
NMR-based metabolomics is a particularly powerful approach when applied to the high-
throughput analysis of biofluids such as blood.[3]NMR spectroscopy has been confirmed to 
be a straightforward and useful technique for the qualitative and quantitative analysis of a 
wide range of components,[11] including low-molecular-weight metabolites, lipids, and 
lipoproteins (different for size and composition). Moreover, high-resolution magic-angle 
spinning (HR-MAS) can be used to measure metabolite concentration in intact tissues,[12, 
13] while magnetic resonance imaging (MRI) and magnetic resonance spectroscopic 
imaging (MRSI) can be used to obtain spatial information on molecules in patients.
The drawback of NMR is that its sensitivity is orders of magnitude lower than MS 
metabolomics. One common approach for increasing the sensitivity is the use of a higher 
magnetic field. Hyperpolarization, which offers a potential different strategy to overcome the 
sensitivity limitation, allows the measurement of chemical reactions in real time. The 
hyperpolarization of selected molecules (e.g., pyruvate) and subsequent injection in a living 
organism can be used in imaging techniques in vivo.[14] This approach allows monitoring of 
tumor metabolism in vivo without radioactive isotopes. While hyperpolarization in MRSI 
allows real-time observation of multiple metabolites, positron emission tomography (PET) is 
still more sensitive.
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Fourier-transform infrared and Raman spectroscopy
Both FT-IR and Raman spectroscopy are spectroscopic techniques that rely on vibrational 
frequencies of metabolites to provide a fingerprint of metabolism.[15] Although selectivity 
and sensitivity are not as high as in NMR and MS, these techniques are able to profile 
carbohydrates, amino acids, lipids, and fatty acids, as well as proteins and polysaccharides, 
simultaneously.[8] They have been recognized as valuable tools for metabolomic 
fingerprinting. While the main drawback of FT-IT is the limitation of using only dried 
samples, Raman spectroscopy can detect metabolites directly from tissues even in vivo.[16
Metabolic profile of normal prostate cells and prostate cancer
Otto Warburg reported that, in normoxic conditions, cancer cells convert glucose to lactate at 
a higher rate than normal cells (the so-called Warburg effect).[17] Although glycolysis is 
less efficient for energy supply than aerobic respiration, it is 100 times faster and provides 
intermediate metabolites from amino acid and pentose phosphate production necessary for 
highly proliferating cancer cells.[18] Although increased aerobic glycolysis is a common 
feature in several malignances, in PCa it is not often present, except in tumors that are purely 
PI3K driven.[19] Altered lipid metabolism is instead a common feature of both primary and 
advanced PCa.[20] Finally, increased lipids, whether synthetized de novo or taken up from 
the circulation, can be utilized for fatty acid oxidation as an important bioenergetics source 
to support cell proliferation and growth.[21, 22] Recently, Raman spectroscopy was used to 
trace the metabolism of PCa in single living cells with high spatial–temporal resolution,[23] 
confirming the dominant fatty acid uptake over glucose uptake in prostate cells.[24
The terminal steps in the de novo biogenesis of fatty acids are catalyzed by the key lipogenic 
enzyme fatty acid synthase (FASN), a metabolic oncogene in PCa.[25, 26] Higher 
concentrations of protein and mRNA were found in PCa[20, 27] and associated with 
aggressive biological behavior.[27] Importantly, the highest levels of FASN expression are 
present in androgen-independent bone metastasis.[20] As mentioned above, unlike most 
tumors, PCa does not show the characteristic glycolytic switch. Thus, primary tumors are 
not efficiently detectable with analogs of glucose like 18F-fludeoxyglucose (FDG) in PET. 
Alternative tracers for PET imaging such as 11C-acetate and 11C-choline have been 
successfully used to detect increased lipid synthesis in PCa cells.[28
A peculiar feature of normal prostate cells is the accumulation and secretion of citrate due to 
the inhibition of the mitochondrial enzyme m-aconitase, which catalyzes the first step of 
citrate oxidation. This enzyme is inhibited by high concentrations of zinc in the prostate 
(which usually present 10- to 20-fold higher than other organs). The concentration of zinc 
decreases when prostate cells undergo neoplastic transformation with a resultant activation 
of m-aconitase and citrate oxidation. Lower concentration of citrate in PCa was reported 
both in seminal/ prostatic fluid[29, 30] by NMR and in prostatic tissue[31] by MRS 
spectroscopy. Citrate showed a stronger correlation with PCa and Gleason score when 
associated with other biomarkers (e.g., choline, creatine, or spermine) by in vivo MRSI[32, 
33] and by ex vivo HR-MAS.[33, 34] However, stroma surrounding primary PCa and bone-
enveloping metastatic disease contribute to the difficulty in analyzing PCa samples by HR-
MAS. Recently, hyperpolarized 13C-pyruvate has been used in MRSI to characterize 
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metabolic alteration in PCa patients.[14] The researchers evaluated the distribution of 
[1-13C]pyruvate and its metabolic products lactate, alanine, and bicarbonate in a time range 
of seconds. The results were extremely promising, showing elevated [1-13C]lactate/
[1-13C]pyruvate in regions of biopsy-proven cancer.
Sarcosine has been found greatly increased by FT-MS during progression from normal tissue 
to PCa and metastatic disease, suggesting a key role in cancer cell invasion and 
aggressiveness.[35] Although the initial controversy surrounding the use of sarcosine as a 
biomarker was due to the difficulty in differentiating it from alanine in GC-MS analyses and 
the absence of internal analytical validation in the first studies,[36] sarcosine has been 
demonstrated to have a role in promoting PCa growth and progression, using both in vitro 
and in vivo models.[37] Quantitative measures of sarcosine, together with alanine, glycine, 
and glutamate, are used in the new commercially available test Prostarix™ to stratify PCa 
risk. More recently, sarcosine levels have been associated with MYC-driven tumors, 
suggesting it may be a biomarker of a molecularly defined category of PCa.[19
Formalin-fixed paraffin-embedded metabolomics
The availability of frozen tissues is often limited. Formalin-fixed paraffin-embedded (FFPE) 
tissue is routinely used in the diagnostic setting, is clinically annotated in databases with 
long-term follow-up and outcome, and exhibits long-term stability when stored at room 
temperature. The ability to use these samples would be of great benefit for PCa studies and 
could help in the discovery and validation of clinically useful biomarkers. FFPE tissue 
collections, accompanied by patient information as well as other molecular determinants, 
indeed represent invaluable resources for translational studies in oncology and other fields.
Yuan et al. recently demonstrated that stored FFPE tissue samples could be used for tumor 
classification and metabolic pathway analysis.[38] The authors described the use of a mass 
spectrometer to profile endogenous polar metabolites by methanol extractions from 
biological samples, without further sample manipulation. The target metabolites covered 
most metabolic pathways, such as glycolysis, the tricarboxylic acid cycle, the pentose 
phosphate pathway, and the metabolism of amino acids and nucleotides. Another study 
examined the technical feasibility and reproducibility of using targeted LC coupled with 
tandem MS (LC-MS/MS) to profile FFPE samples.[39] In this study, the authors profiled a 
set of five FFPE soft tissue sarcoma specimens and five paired normal tissue samples by LC-
MS/MS. We recently were able to detect almost 400 metabolites in FFPE PCa cells and 
tissues, including lipids, amino acids, carbohydrates, nucleotides, cofactors, and vitamins 
(Cacciatore et al., unpublished observation). Interestingly, metabolomics signatures obtained 
from these samples were able to discriminate tumor from adjacent normal tissues.
However, the metabolic analysis of FFPE is limited by sensitivity of the mass spectrometer, 
and it does not allow the detection of some classes of metabolites. Moreover, steps in the 
procedures of FFPE, such as the time used to fix the tissue, can strongly affect the 
concentration of some metabolites. Unfortunately, the time of fixation is usually not 
available. The ability to perform such analyses in FFPE tissues paves the way for 
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metabolomics-based biomarker discovery and validation using large retrospective and 
clinically well-defined FFPE sample collections.
Oncogenes and metabolic profiles
Cancer cells may overcome growth factor dependence by deregulating oncogenic and/or 
tumor suppressor pathways that affect their metabolism, or by activating metabolic pathways 
de novo with targeted mutations in critical metabolic enzymes. The oncogene MYCregulates 
several aspects of cellular biology including anaerobic glycolysis[40] and glutaminolysis.
[41, 42] Recently, distinct lipid profiles in high and low MYC expression states were 
observed in lymphomas,[43] suggesting a relationship between the lipid metabolism and the 
overexpression of MYC.
In a recent study,[19] the metabolic reprogramming of two different oncogenes (AKT and 
MYC) was characterized in cells, murine models, and human PCa. MS-based metabolite 
profiling was performed on immortalized human prostate epithelial cells transformed by 
AKT1 or MYC, transgenic mice driven by the same oncogenes under the control of a 
prostate-specific promoter, and human prostate specimens characterized for the expression 
and activation of these oncoproteins. Integrative analysis of these metabolomic datasets 
revealed that AKT1 activation was associated with accumulation of aerobic glycolysis 
metabolites, whereas MYC overexpression was associated with dysregulated lipid 
metabolism. These data show how prostate tumors undergo a metabolic reprogramming that 
reflects their molecular phenotypes, with implications for the development of metabolic 
diagnostics and targeted therapeutics.
De novo fatty acid synthesis at the mitotic exit
Cellular metabolism plays a key role in cancer cell proliferation. The high rate of growth in 
cancer cells is accomplished by the activation of growth signaling and metabolic pathways 
allowing greater nutrient uptake and an increase in macromolecular biosynthesis. Transition 
from G1 to S is regulated by the complex interplay between G1 cyclins, cyclin-dependent 
kinases (CDKs) and their inhibitors, the retinoblastoma proteins (pRBs), and E2F-dependent 
events, but the effects of the metabolic reprogramming on the cell cycle remain elusive.[44]
Using MS-based metabolomics, a decrease in lysophospholipids was observed during the 
transition from G2/M to G1 phase despite an increase in the de novo synthesis of fatty acids 
and phosphatidylcholine,[45] suggesting that enhanced membrane production was related to 
a decrease in its turnover. The arrest of the cell at G2/M for the inhibition of fatty acid 
synthesis indicates that the membrane production starts before G1 and it is necessary to 
complete cellular division. Importantly, it also highlights evidence of closer cross talk 
between metabolism and the cell cycle, showing that the inhibition of fatty acid synthesis 
can block cell growth at G2/M with high concentration of fatty acids in the media. This 
study suggested that the cell cycle completion is fundamental for de novo lipogenesis. This 
“lipogenic checkpoint” should be investigated further for therapeutic application in PCa. 
This study underlines the importance of metabolomics as a tool to view the biochemical 
changes during cell proliferation in cancer.
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Conclusion
Metabolomics aims to acquire robust and reproducible quantitative information, but there is 
not a unique platform able to capture the entire metabolome.
MS is the most sensitive technique and can be used for the quantification of a wide spectrum 
of known molecules. Ultrahigh-accuracy mass spectrometers allow the detection and 
quantification of thousands of metabolites in a single-run experiment. NMR spectroscopy 
has a very limited sensitivity but it can extract information from a range of molecules 
normally difficult to assess by MS, such as lipoprotein particles in blood. In addition, NMR 
is a nondestructive technique and it can be applied successfully to the measure of 
metabolites in intact tissue or even in vivo in the whole body. NMR spectroscopy and MS 
are complementary techniques, and both methods are needed to obtain a comprehensive 
view of the metabolome.
On the other hand, FT-IR and Raman spectroscopy are rapid, robust, and highly reproducible 
analytical techniques, which detect only a subset of the metabolome without providing the 
concentration of single metabolites. Emerging techniques for imaging biological tissues 
based on Raman spectroscopy (e.g., stimulated Raman scattering microscopy) show 
considerable potential for the detection of specific classes of components (e.g., lipids) in 
vivo in single cells with high spatial–temporal resolution.
Most metabolomic research on PCa has focused on relatively small groups of metabolites 
that have long been known to be relevant to the prostate, such as citrate, choline, and 
polyamines. Efforts at more global profiling of the prostate metabolome are increasing, and 
are benefitting from advances in bioinformatics that accompany high-dimensional genomics 
and proteomics data analysis. Although metabolomic technologies have improved and 
evidence is accumulating to support their use in clinical decision making, the discipline is 
still in its infancy. The integration of the metabolomic with other high-throughput 
approaches will offer incredible opportunities, and large retrospective and clinically well-
defined FFPE sample collection will be useful to bring us closer to the goal of personalized 
medicine.
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